Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Silence Therapeutics ( (SLN) ) has shared an announcement.
Silence Therapeutics will transition to filing reports as a U.S. domestic issuer starting January 1, 2025, which entails using more detailed and prompt SEC forms compared to those for a foreign private issuer. This change reflects the company’s growth and could impact its transparency and engagement with stakeholders, as it also utilizes multiple channels to disseminate material information broadly.
More about Silence Therapeutics
Silence Therapeutics plc operates in the biotechnology industry, focusing on developing RNA interference (RNAi) therapeutics. The company’s primary products include potential product candidates Zerlasiran and Divesiran, as well as its proprietary mRNAi GOLD™ platform.
Average Trading Volume: 492,109
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $321M
For a thorough assessment of SLN stock, go to TipRanks’ Stock Analysis page.
